236 related articles for article (PubMed ID: 30206802)
1. Combined radiotherapy with nivolumab for extracranial metastatic malignant melanoma.
Komatsu T; Konishi K; Aoshima M; Tokura Y; Nakamura K
Jpn J Radiol; 2018 Dec; 36(12):712-718. PubMed ID: 30206802
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab.
Nomura M; Otsuka A; Yoshimura M; Nonomura Y; Kaku Y; Matsumoto S; Muto M
Cancer Chemother Pharmacol; 2018 May; 81(5):823-827. PubMed ID: 29502140
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma.
Sundahl N; Seremet T; Van Dorpe J; Neyns B; Ferdinande L; Meireson A; Brochez L; Kruse V; Ost P
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):828-835. PubMed ID: 30951807
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study.
Namikawa K; Takahashi A; Mori T; Tsutsumida A; Suzuki S; Motoi N; Jinnai S; Kage Y; Mizuta H; Muto Y; Nakano E; Yamazaki N
Melanoma Res; 2020 Feb; 30(1):76-84. PubMed ID: 31095037
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma.
Koppolu V; Rekha Vasigala VK
J Cancer Res Ther; 2018; 14(6):1167-1175. PubMed ID: 30488824
[TBL] [Abstract][Full Text] [Related]
6. Primary malignant melanoma of the esophagus, treated with immunotherapy: a case report.
Rochefort P; Roussel J; de la Fouchardière A; Sarabi M; Desseigne F; Guibert P; Cattey-Javouhey A; Mastier C; Neidhardt-Berard EM; de la Fouchardière C
Immunotherapy; 2018 Aug; 10(10):831-835. PubMed ID: 30073896
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab (OPDIVOO) BRAF V600 mutation-negative metastatic or inoperable melanoma: survival advantage.
Prescrire Int; 2016 Dec; 25(177):289-292. PubMed ID: 30758924
[TBL] [Abstract][Full Text] [Related]
8. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281
[TBL] [Abstract][Full Text] [Related]
9. Bicytopenia in Primary Lung Melanoma Treated with Nivolumab.
Takahashi A; Kubo A; Mizuno S; Kasai K; Asai N; Yonezawa T; Kosaka K; Nishimura M; Tanaka H; Yokoe N; Tsuzuki T; Takami A; Yamaguchi E
Intern Med; 2019 Mar; 58(6):827-831. PubMed ID: 30449777
[TBL] [Abstract][Full Text] [Related]
10. Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports.
Schliep S; Agaimy A; Cavallaro A; Kiesewetter F; Schuler G; Heinzerling L
J Immunother Cancer; 2018 Jan; 6(1):2. PubMed ID: 29332608
[TBL] [Abstract][Full Text] [Related]
11. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
[TBL] [Abstract][Full Text] [Related]
12. Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma.
Ikeda T; Yamaguchi H; Dotsu Y; Taniguchi H; Gyoutoku H; Senju H; Sakamoto N; Iwanaga S; Kuwatsuka Y; Fukuda M; Mukae H
Thorac Cancer; 2018 Nov; 9(11):1522-1524. PubMed ID: 30253076
[TBL] [Abstract][Full Text] [Related]
13. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
14. Profile fluctuation of peripheral blood in advanced melanoma patients treated with nivolumab.
Saito R; Sawada Y; Saito-Sasaki N; Yamamoto K; Yoshioka H; Ohmori S; Yoshioka M; Okada E; Nakamura M
J Dermatol; 2018 Dec; 45(12):1452-1455. PubMed ID: 30204257
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab.
Nomura M; Otsuka A; Kondo T; Nagai H; Nonomura Y; Kaku Y; Matsumoto S; Muto M
Cancer Chemother Pharmacol; 2017 Nov; 80(5):999-1004. PubMed ID: 28983657
[TBL] [Abstract][Full Text] [Related]
16. Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer.
Desideri I; Francolini G; Scotti V; Pezzulla D; Becherini C; Terziani F; Delli Paoli C; Olmetto E; Visani L; Meattini I; Greto D; Bonomo P; Loi M; Detti B; Livi L
Clin Transl Oncol; 2019 Jul; 21(7):933-938. PubMed ID: 30565084
[TBL] [Abstract][Full Text] [Related]
17. Dramatic response to nivolumab after local radiotherapy in pulmonary pleomorphic carcinoma with rapid progressive post-surgical recurrence.
Yaguchi D; Ichikawa M; Ito M; Okamoto S; Kimura H; Watanabe K
Thorac Cancer; 2019 May; 10(5):1263-1266. PubMed ID: 30860657
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy.
Nakamura Y; Kitano S; Takahashi A; Tsutsumida A; Namikawa K; Tanese K; Abe T; Funakoshi T; Yamamoto N; Amagai M; Yamazaki N
Oncotarget; 2016 Nov; 7(47):77404-77415. PubMed ID: 27764805
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.
Ribeiro Gomes J; Schmerling RA; Haddad CK; Racy DJ; Ferrigno R; Gil E; Zanuncio P; Buzaid AC
J Immunother; 2016; 39(9):367-372. PubMed ID: 27741091
[TBL] [Abstract][Full Text] [Related]
20. Predicting marker for early progression in unresectable melanoma treated with nivolumab.
Kondo T; Nomura M; Otsuka A; Nonomura Y; Kaku Y; Matsumoto S; Muto M
Int J Clin Oncol; 2019 Mar; 24(3):323-327. PubMed ID: 30168088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]